FUNDAMENTALS |
MarketCap: |
18 172 mill
|
EPS: |
-3.52
|
P/E: |
-40.83
|
Earnings Date: |
May 02, 2024 |
SharesOutstanding: |
126.45 mill
|
Avg Daily Volume: |
0.849 mill
|
RATING
2024-04-25 |
B-
|
Neutral
|
RATINGS |
Rating CashFlow: |
Strong Buy
|
|
Return On Equity: |
Strong Buy
|
|
Return On Asset: |
Sell
|
|
DE: |
Strong Sell
|
|
P/E: |
Strong Sell
|
|
Price To Book: |
Strong Sell
|
|
QUARTER GROWTHS |
|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE -40.83 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
-6.95x
|
Company: PE -40.83 | industry: PE 5.88
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ 139.31 - 148.11
( +/- 3.06%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2024-03-20 | Fitzgerald Kevin Joseph | Sell | 0 | Common Stock |
2024-03-20 | Fitzgerald Kevin Joseph | Buy | 0 | Common Stock |
2021-02-11 | Fitzgerald Kevin Joseph | Sell | 9 000 | Performance Stock Option 2017 (right to buy) |
2024-03-20 | Fitzgerald Kevin Joseph | Sell | 16 250 | Stock Option (right to buy) |
2024-03-20 | Fitzgerald Kevin Joseph | Sell | 6 667 | Stock Option (right to buy) |
INSIDER POWER |
-6.10
|
Last
99 transactions |
Buy:
237 064 | Sell:
275 392 |
Forecast:
16:00 - $143.67
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $143.67
Forecast 2: 16:00 - $143.67
Forecast 3: 16:00 - $143.67
SCORE
-9.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$143.71 (-0.06% )
|
Volume |
0.477 mill
|
Avg. Vol. |
0.849 mill
|
% of Avg. Vol |
56.17 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For ALNY
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date |
Signal |
@ |
Closed |
% |
Feb 8 - 15:36 | sell | $168.89 | N/A | Active |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.